The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.0M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 695K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

58 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
ExploringEBI
University of California San Francisco
Alanine mutants of the interface residues of human thymidylate synthase decode key features of the binding mode of allosteric anticancer peptides.EBI
University of California San Francisco
Analogs of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, as Anti-Cancer Agents.EBI
University of California San Francisco
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.EBI
University of California San Francisco
Features of selective kinase inhibitors.EBI
University of California San Francisco
Colloid formation by drugs in simulated intestinal fluid.EBI
University of California San Francisco
Characterization of thyroid hormone receptor alpha (TRalpha)-specific analogs with varying inner- and outer-ring substituents.EBI
University of California San Francisco
Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase.EBI
University of California San Francisco
Reaching for high-hanging fruit in drug discovery at protein-protein interfaces.EBI
University of California San Francisco
Exploring the structure-activity relationship of the ethylamine portion of 3-iodothyronamine for rat and mouse trace amine-associated receptor 1.EBI
University of California San Francisco
Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics.EBI
University of California San Francisco
Decoys for docking.EBI
University of California San Francisco
Soft docking and multiple receptor conformations in virtual screening.EBI
University of California San Francisco
Prediction of the binding free energies of new TIBO-like HIV-1 reverse transcriptase inhibitors using a combination of PROFEC, PB/SA, CMC/MD, and free energy calculations.EBI
University of California San Francisco
Design, synthesis, crystal structures, and antimicrobial activity of sulfonamide boronic acids asß-lactamase inhibitors.EBI
University of California San Francisco
Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors.EBI
University of California San Francisco
6-Azido-7-nitro-1,4-dihydroquinoxaline-2,3-dione (ANQX) forms an irreversible bond to the active site of the GluR2 AMPA receptor.EBI
University of California San Francisco
Trace amine-associated receptor 1 (TAAR1) is activated by amiodarone metabolites.EBI
University of California San Francisco
Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits.EBI
University of California San Francisco
A high-throughput screen for aggregation-based inhibition in a large compound library.EBI
University of California San Francisco
Small molecule inhibitors of intestinal epithelial anion exchanger SLC26A3 (DRA) with a luminal, extracellular site of action.EBI
University of California San Francisco
Structure-Based Discovery of Inhibitors of the SARS-CoV-2 Nsp14 N7-Methyltransferase.EBI
University of California San Francisco
Trace amine-associated receptor agonists: synthesis and evaluation of thyronamines and related analogues.EBI
University of California San Francisco
Drugging the Next Undruggable KRAS Allele-Gly12Asp.EBI
University of California San Francisco
Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain.EBI
University of California San Francisco
Design and evaluation of novel nonsteroidal dissociating glucocorticoid receptor ligands.EBI
University of California San Francisco
Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi.EBI
University of California San Francisco
A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics simulations.EBI
University of California San Francisco
A Phosphoramidate Strategy Enables Membrane Permeability of a Non-nucleotide Inhibitor of the Prolyl Isomerase Pin1.EBI
University of California San Francisco
LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates.EBI
University of California San Francisco
Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain.EBI
University of California San Francisco
Dual antagonists of α5β1/αvβ1 integrin for airway hyperresponsiveness.EBI
University of California San Francisco
The impact of introducing a histidine into an apolar cavity site on docking and ligand recognition.EBI
University of California San Francisco
Cloning and functional expression of a human liver organic cation transporter.EBI
University of California San Francisco
The interaction of n-tetraalkylammonium compounds with a human organic cation transporter, hOCT1.EBI
University of California San Francisco
Human dipeptide transporter, hPEPT1, stably transfected into Chinese hamster ovary cells.EBI
University of California San Francisco
Substrate analog studies of the ω-regiospecificity of Mycobacterium tuberculosis cholesterol metabolizing cytochrome P450 enzymes CYP124A1, CYP125A1 and CYP142A1.EBI
University of California San Francisco
Reverse type I inhibitor of Mycobacterium tuberculosis CYP125A1.EBI
University of California San Francisco
Small-molecule aggregates inhibit amyloid polymerization.EBI
University of California San Francisco
Selectivity Challenges in Docking Screens for GPCR Targets and Antitargets.EBI
University of California San Francisco
Neuroactive steroids, compositions, and uses thereofBDB
Sage Therapeutics
Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of diseaseBDB
Merck Sharp & Dohme
Ethynyl derivativesBDB
Hoffmann-La Roche
Compounds that are ERK inhibitorsBDB
Merck Sharp & Dohme
Aldosterone synthase inhibitorsBDB
Boehringer Ingelheim International
InhibitorsBDB
Probiodrug
Ghrelin O-acyl transferase inhibitorsBDB
Eli Lilly
ERRgamma tethers strongly bisphenol A and 4-alpha-cumylphenol in an induced-fit manner.BDB
Kyushu University
Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities.BDB
Bristol-Myers Squibb
Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity.BDB
Glaxosmithkline
Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors.BDB
F. Hoffmann-La Roche
Novel heterobivalent tacrine derivatives as cholinesterase inhibitors with notable selectivity toward butyrylcholinesterase.BDB
Rheinische Friedrich-Wilhelms-Universitat Bonn
A structure-based design approach to the development of novel, reversible AChE inhibitors.BDB
Syngenta
Novel pyrrolyllactone and pyrrolyllactam indolinones as potent cyclin-dependent kinase 2 inhibitors.BDB
Sugen